Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
108 participants
INTERVENTIONAL
2017-01-15
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present study is the first randomized controlled trial of group mindfulness-based intervention for psychosis. Half group will join the mindfulness-based cognitive intervention while another half will participate in psychoeducation to examine whether mindfulness will have a positive impact on emotion regulation and distress.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mindfulness Group-based Intervention for Early Psychosis
NCT03143907
Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study
NCT02342210
Mindfulness Psychoeducation Program for Schizophrenia
NCT03632278
Mindfulness-based Illness Management Program for Schizophrenia
NCT01667601
Mindfulness-based Social Cognition Training for Psychosis (SocialMind): A Feasibility Study
NCT03434405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Affective symptoms are a significant risk factor accounting for approximately 5-6% of suicide rates which remain or becomes higher shortly after a psychotic episode or hospital discharge (American Psychiatric Association, 2013). It has been proved that the emotion management and cognitive reappraisal were negatively associated with schizophrenia.
In the study, it is hypothesized that the intervention will have a positive impact on psychotic symptoms, general symptoms such as affective symptoms, psychological flexibility, mindfulness skills, quality of life and re-hospitalization by facilitating strategies on emotion regulation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Eligible participants will be randomly assigned to receive Mindfulness-based Cognitive Therapy for Psychosis (MBCTp) plus TAU or TAU plus Psychoeducation for Psychosis (PEp).
Simple randomization will be used to ensure that participants will have equal opportunity to be included into the study (Altaman and Bland, 1999).
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mindfulness-based intervention
Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
Mindfulness-based cognitive therapy (psychosis)
A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
Psychoeducation
Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
Psychoeducation (psychosis)
A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness-based cognitive therapy (psychosis)
A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
Psychoeducation (psychosis)
A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a primary diagnosis of psychosis (non-affective) and/or other psychotic disorders met the Diagnostic and Statistical Manual DSM-5
* Have been diagnosed equivalent to or less than 5 years
* Mentally stable as assessed by the researcher and a psychiatrist to comprehend the education and training provided (a pre-recruitment briefing session for potential participants will be conducted to verify their ability to follow instructions and understanding in participation, and case files will be reviewed to ensure a stable medication regime for at least 6 months) in order to ensure their ability to make a valid consent
* Able to read and understand Chinese
Exclusion Criteria
* Have comorbidities (a) developmental impairment (b) learning disability, (c) personality disorders, and/or (d) any clinically significant medical diseases (by case-file review).
* Have organic psychosis or a primary drug or alcohol addiction
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Edinburgh Napier University
OTHER
The Hong Kong Polytechnic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
YIP Lai King
Senior Clinical Associate
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thanos Karatzias
Role: STUDY_DIRECTOR
Edinburgh Napier University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Fourth People's Hospital
Chengdu, , China
The Society of Rehabilitation and Crime Prevention
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSEARS20170811001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.